● The stock, which is currently worth 2021 to 0.13 times its sales, is clearly overvalued in comparison with peers.
● The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
● Technically, the stock approaches a strong medium-term resistance at EUR 12.81.
● The company has insufficient levels of profitability.
● Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
● The company's earnings releases usually do not meet expectations.
● The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
● For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
● Analysts covering the stock have recently lowered their earnings forecast.
● For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
● For the past year, analysts have significantly revised downwards their profit estimates.